An observational study in Eosinophilic Esophagitis, sponsored by Sociedad Espanola de Gastroenterologia, Hepatologia y Nutricion Pediatrica. Status unknown at 1 site in Spain. Open to participants aged 1 Month to 18 Years. Per ClinicalTrials.gov, last updated 2019-02-28.
Sponsored by Sociedad Espanola de Gastroenterologia, Hepatologia y Nutricion Pediatrica · Observational
Registry of patients treated with PPI:
Registry of patients treated with two foods elimination diet:
Registry of patients treated with swallowed steroids (budesonide or fluticasone):
322 studies on the registry are indexed under Esophagitis; 37 are open to participants now.
This study's planned enrollment of 500 is above the median of 100 across 91 observational studies indexed under Esophagitis.
Browse Esophagitis studies →This is the only study on the registry with Sociedad Espanola de Gastroenterologia, Hepatologia y Nutricion Pediatrica as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Children from 1 month to 18 years with a new diagnosis of eosinophilic esophagitis according to the recent European guidelines
Exclusion Criteria:
Inclusion criteria: * Children from 1 month to 18 years with a new diagnosis of eosinophilic esophagitis according to recent European guidelines (symptoms of esophageal dysfunction + eosinophilic infiltrate of the esophagus \> 15 eos / CGA) * And they need to start treatment with one of the following options: PPI, diet excluding cow's milk and gluten, or swallowed corticosteroids Exclusion criteria: * Presence of pathological eosinophilia at the gastric or duodenal level (eosinophilic gastroenteritis) * Simultaneous treatment with more than one treatment modality (PPI, empirical elimination diet, swallowed corticosteroids).
Other: no intervention
no intervention
Complete histological remission
Complete histological remission response defined as ≤5 eosinophils/hpf in all biopsies performed
Time frame: 12 weeks
Partial histological remission
Partial histological remission response defined as 5-15 eosinophils /hpf in all biopsies
Time frame: 12 weeks
Clinical remission
Clinical remission (specific questionnaire)
Time frame: 12 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.